RP-HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
== Mechanism of action == Chloramphenicol is a bacteriostatic agent, inhibiting protein synthesis. It prevents protein chain elongation by inhibiting the peptidyl transferase activity of the bacterial ribosome. It specifically binds to A2451 and A2452 residues in the 23S rRNA of the 50S ribosomal subunit, preventing peptide bond formation. Chloramphenicol directly interferes with substrate binding in the ribosome, as compared to macrolides, which sterically block the progression of the growing peptide.
Glycolipid transfer protein is a cytosolic protein that catalyses the transfer of glycolipids between different intracellular membranes. It was discovered by Raymond J. Metz and Norman S. Radin in 1980 and partially purified and characterized in 1982. Recent reviews on structure and possible function are available. This protein transports primarily different glycosphingolipids and glyceroglycolipids between intracellular membranes, but not phospholipids. It might be also involved in translocation of glucosylceramides. It was found in brain, kidney, spleen, lung, cerebellum, liver and heart.
dissociation Any process by which a polyatomic molecule or molecular entity (e.g. an ionic compound or coordination complex), or an aggregate of molecular entities, separates or splits into two or more molecules, atoms, ions, radicals, or other constituents, usually in a reversible manner. Examples include unimolecular heterolysis and homolysis, the dissolution of salts, and acid dissociation. Contrast association.
=== Agonists === Finding selective agonists for PAR1 has also been a topic of interest for researchers. A synthetic SFLLRN peptide has been found to serve as an agonist for PAR1. The SFLLRN peptide mimics the first six residues of the N-terminal tethered ligand of activated PAR1 and binds to the same binding site on the second extracellular loop. So, even in the absence of thrombin, SFLLRN binding can garner a response from cleaved or uncleaved PAR1.
Sources: en.wikipedia.org
=== Coffee consumption === Epidemiological studies show that coffee consumption is associated with decreased mortality and lower rates of some neurological diseases, including Parkinson's disease and type 2 diabetes. Coffee beans and roasted coffee can contain hundreds of individual compounds, including caffeine, chlorogenic acid (CGA), quercetin, trigonelline, caffeic acid, and phenylindane. Underlying mechanisms are not yet understood.
== Usage == Drug use among elderly Americans has been studied; in a group of 2,377 people with an average age of 71 surveyed between 2005 and 2006, 84% took at least one prescription drug, 44% took at least one over-the-counter (OTC) drug, and 52% took at least one dietary supplement; in a group of 2245 elderly Americans (average age of 71) surveyed over the period 2010 – 2011, those percentages were 88%, 38%, and 64%.
=== Annealing based connection of oligonucleotides === Usually, a set of individually designed oligonucleotides is made on automated solid-phase synthesizers, purified and then connected by specific annealing and standard ligation or polymerase reactions. To improve specificity of oligonucleotide annealing, the synthesis step relies on a set of thermostable DNA ligase and polymerase enzymes. To date, several methods for gene synthesis have been described, such as the ligation of phosphorylated overlapping oligonucleotides, the Fok I method and a modified form of ligase chain reaction for gene synthesis. Additionally, several PCR assembly approaches have been described. They usually employ oligonucleotides of 40-50 nucleotides length that overlap each other. These oligonucleotides are designed to cover most of the sequence of both strands, and the full-length molecule is generated progressively by overlap extension (OE) PCR, thermodynamically balanced inside-out (TBIO) PCR or combined approaches. The most commonly synthesized genes range in size from 600 to 1,200 bp although much longer genes have been made by connecting previously assembled fragments of under 1,000 bp. In this size range it is necessary to test several candidate clones confirming the sequence of the cloned synthetic gene by automated sequencing methods.
Official website of UK Bat Conservation Trust Tree of Life Archived 26 July 2020 at the Wayback Machine Microbat Vision Archived 29 January 2020 at the Wayback Machine Analyses of several kinds of bat echolocation
== Clinical significance == Collagen XXIII plays a role as a biomarker for detection and recurrence of NCLSC cells (non-small cell lung carcinoma) and the reappearance of prostate cancer. Some experiments suggest that collagen XXIII influences cellular adhesion and stimulates metastasis development by facilitating cancer cells growth and survival when they are rounded and not able to spread. It has been shown that loss of collagen XXIII may complicate cellular adhesion and reduce lung cancer cell retention.
Sources: en.wikipedia.org
=== Fibroblast-populated skin substitutes === Fibroblast-populated Skin Substitutes are scaffolds which contain fibroblasts that are able to proliferate and produce extracellular matrix and growth factors within 2 to 3 weeks. This creates a matrix similar to that of a dermis. Commercially available types are for example:
=== Second independence (2025–present) === Sumo Group was acquired by Tencent in 2022, and in early 2025, underwent a management change with a goal of focusing only on co-development work using licensed intellectual property. As part of this change, the Chinese Room had around a dozen staff downsized in June 2025. In July 2025, the Chinese Room was bought out by management with help from Hiro Capital, with studio head Ed Daly continuing to lead the company. The studio said the buyout was done to avoid being sold off by the Sumo Group to another publisher or private equity group. Daly said the buyout "allows us to scratch the creative itch of continuing to work on new, original intellectual property, but also to partner with other studios on other projects when they fit in with our vision". In February 2026, the Chinese Room announced a publishing deal with Lyrical Games for a new game.
== History == The Inca were freeze drying potatoes into chuño since the 13th century. The process involved multiple cycles of exposing potatoes to below freezing temperatures on mountain peaks in the Andes during the evening, and squeezing water out and drying them in the sunlight during the day. The Inca people also used the unique climate of the Altiplano to freeze dry meat. The Japanese koya-dofu, freeze-dried tofu, dates to the mid-1500s in Nagano and the 1600s on Mount Koya. These methods are similar but not technically equivalent to the modern process of freeze-drying which requires access to both refrigeration and vacuum systems. Modern freeze drying began as early as 1890 by Richard Altmann who devised a method to freeze dry tissues (either plant or animal), but went virtually unnoticed until the 1930s. In 1909, L. F. Shackell independently created the vacuum chamber by using an electrical pump. No further freeze drying information was documented until Tival in 1927 and Elser in 1934 had patented freeze drying systems with improvements to freezing and condenser steps. A significant turning point for freeze drying occurred during World War II when blood plasma and penicillin were needed to treat the wounded in the field. Because of the lack of refrigerated transport, many serum supplies spoiled before reaching their recipients. The freeze-drying process was developed as a commercial technique that enabled blood plasma and penicillin to be rendered chemically stable and viable without refrigeration.
As a sign of the expanding commercial ties between the two regions (and Han and Tibetan peoples in particular), a special exhibition was held in Chengdu, so that Sichuanese may see and come into contact with Xikang products. In order to levy taxes from the region, Liu also established a Finance Ministry. Historians and analysts have debated over the effectiveness of these measures. Yang Zhonghua, writing in 1941, praised them as a relatively proactive policy; however, it has been argued by Xie Benzao that Liu's plans, though ambitious on paper, were limited by the realities of war and mostly for the purpose of resource extraction. Another road-building project of Liu Wenhui, constructed in the late 1920s from Yazhou to Chengdu, was known by locals mainly for the ruthlessness of its methods. Despite these projects, Xikang was mostly seen as a rear location distant from the conflicts in Sichuan. Liu encouraged students from Sichuan to take part in "border construction" in Xikang. In September 1929, he set up a newsletter, Bianzheng (邊政), dedicated to frontier administration. The issues of the Bianzheng promoted Sun Yat-sen's Three Principles and advertised Xikang as an attractive region for Chinese settlement, teeming with resources but nonetheless coveted by British imperialists. Propaganda plays published in the newsletter, which can be seen as the official policy of Liu Wenhui's government, exhorted youths to settle and develop the Xikang frontier, despite hardships, and thwart the imperialist plans of Tibet and Britain.
=== American Cancer Society === Inhorn's ongoing interest in cervical cancer was the reason that he joined the American Cancer Society, Wisconsin Division, in 1967. He was Chair of the State Cancer Prevention Study II, and in 1986, he headed a demonstration project with a number of Wisconsin hospitals to determine the acceptance of offering low-cost mammography as a screening test for breast cancer. Inhorn served as President of the Wisconsin Division from 1970 to 1972, continuing on the board until 2010. He also served on the national American Cancer Society Board from 1982 to 1990.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.